908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: 908devices.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2025 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 11/13/2024 | $12.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 2/7/2023 | $14.00 | Overweight | Stephens |
| 3/8/2022 | $40.00 → $30.00 | Outperform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
Fastest customizable press release news feed in the world
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 Devices Inc. in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the 908 Devices Inc. 2026 Inducement Plan (the "Plan"). The inducement stock option has an exercise price of $8.63 per share, which is equal to the cl
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on Wednesday, June 10, 2026. The Company presentation is scheduled to begin at 8:35 a.m. Eastern Time. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the company website at: www.908devices.com. About 908 Devices 908 Devices is
Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR Acquired NIRLAB AG, expanding narcotics identification capabilities 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. "We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion," said Kevin J. Knopp, CEO and Co-founder. "We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segm
Strategic acquisition adds integrated hardware and cloud subscription platform powered by NIR spectroscopy 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcotics detection with NIRLAB's solution for fast, high-volume screening for everyday law enforcement patrol. The NIRLAB handhel
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld dev
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr. Otitoju brings over 25 years of proven executive leadership in strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will virtually present and host investor meetings at the Sidoti Small Cap Conference on Wednesday, March 18, 2026. The Company presentation is scheduled to begin at 1:45 p.m. Eastern Time. A live audio webcast of the event with accompanying slides can be accessed here: https://sidoti.zoom.us/webinar/register/WN_rb94-xr9QPyFewc5E6MmJQ. Interested parties may access an archived webcast of the presentation on the "Investors" section of the company
Fourth quarter 2025 revenue increased 21% compared to prior year Achieved positive Adjusted EBITDA in the fourth quarter 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year 2025, increasing 18% compared to the full year 2024 Recurring revenue was $19.5 million for the full
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences. TD Cowen 46th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 4 at 9:10 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Monday, March 9 at 1:40 p.m. Eastern Time Interested parties may access a live and archived webcast of these sessions on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 Devices is revolutionizing chemical a
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its si
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Leerink Partners upgraded 908 Devices from Market Perform to Outperform and set a new price target of $12.00
Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously
Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously
Cowen resumed coverage of 908 Devices with a rating of Outperform
SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $65.00 from $70.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
144 - 908 Devices Inc. (0001555279) (Subject)
SD - 908 Devices Inc. (0001555279) (Filer)
SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)
10-Q - 908 Devices Inc. (0001555279) (Filer)
8-K - 908 Devices Inc. (0001555279) (Filer)
DEFA14A - 908 Devices Inc. (0001555279) (Filer)
DEF 14A - 908 Devices Inc. (0001555279) (Filer)
144 - 908 Devices Inc. (0001555279) (Subject)
EFFECT - 908 Devices Inc. (0001555279) (Filer)
S-3 - 908 Devices Inc. (0001555279) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
4 - 908 Devices Inc. (0001555279) (Issuer)
Live Leadership Updates
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr. Otitoju brings over 25 years of proven executive leadership in strategy, business development, and P&L management across the medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors due to the company's strategic refocus on public health, safety and defense tech. These changes are effective immediately. Previously, Dr. Vann was Performing the Duties of the Assistant Secretary of Defense for Nuclear, Ch
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as
Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod
Company Appoints Six New Members to its Scientific Advisory Board 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Professor Michael Betenbaugh, Dr. Tim Charlebois, Dr. Elena Chernokalskaya, Dr. John Erickson, Professor Krishnedndu Roy and Dr. Gene Schaefer. The new SAB members join the board's co-chairs Christopher D. Brown, CTO of 908 Devices, and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill. "We are honored to be welcoming Michael, Tim, Elena, John
Experienced HR executive with global tech background joins executive leadership team 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles, Michele will lead human resource strategies, processes, and systems to optimize business and talent outcomes for 908 Devices. In this new role, Michele will build a strong talent acquisition pipeline, promote inclusion and diversity in the workplace, and help shape and define employee car
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors, effective immediately. Mr. George brings more than two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He served as the global division head and CEO of two $10 billion divisions of Novartis, Sandoz and Alcon, between 2008 and 2016, where in parallel he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharm
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the appointment of industry veteran Steve Davenport as Vice President of Commercial Sales. Contributing to the record number of life sciences companies that went public in 2020, 908 Devices is now executing on its vision by bolstering the leadership team as it builds out channels to reach and serve bioprocess customers. “The bioprocessing market is an exciting growth area for us as our products help biologists and researchers accelerate therapeutic development,” said Dr. Kevin J. Knopp, CEO of 908 Devices. “H
This live feed shows all institutional transactions in real time.
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
SC 13G/A - 908 Devices Inc. (0001555279) (Subject)
Live finance-specific insights
Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR Acquired NIRLAB AG, expanding narcotics identification capabilities 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. "We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion," said Kevin J. Knopp, CEO and Co-founder. "We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segm
Strategic acquisition adds integrated hardware and cloud subscription platform powered by NIR spectroscopy 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcotics detection with NIRLAB's solution for fast, high-volume screening for everyday law enforcement patrol. The NIRLAB handhel
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld dev
Fourth quarter 2025 revenue increased 21% compared to prior year Achieved positive Adjusted EBITDA in the fourth quarter 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year 2025, increasing 18% compared to the full year 2024 Recurring revenue was $19.5 million for the full
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its si
Year-to-date revenue increased 16% while Adjusted EBITDA loss improves 53% quarter over quarter 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended September 30, 2025. "We are pleased with our year-to-date progress as we continue to build a more predictable and profitable business and bring our 908 Devices 2.0 vision to life," said Kevin J. Knopp, CEO and Co-founder. "Revenue for the first nine months increased 16%, with strong FTIR demand and with 47% of revenues coming from our U.S. state and local channel. T
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the third quarter 2025 before market open on Monday, November 10, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical ana
Revenue from continuing operations grew 14% compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. "We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile," said Kevin J. Knopp, CEO and Co-founder. "We delivered record XplorIR placements, successfully launched VipIR, and made meaningful progress on our path to profitability. These achievements reinforce our c
908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the second quarter 2025 before market open on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical an
Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in